Research programme: G protein-coupled receptor modulators - AstraZeneca/Galapagos
Latest Information Update: 13 Apr 2007
At a glance
- Originator AstraZeneca; Galapagos NV
- Class
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus; Obesity
Most Recent Events
- 13 Apr 2007 No development reported - Preclinical for Diabetes mellitus in USA (unspecified route)
- 13 Apr 2007 No development reported - Preclinical for Obesity in USA (unspecified route)
- 04 Nov 2005 BioFocus has been acquired and merged into Galapagos NV